Top Players and Competitive Dynamics in the Night Blindness Treatment Market

The night blindness treatment market is on track for substantial growth over the coming years, fueled by advancements in medical technology and rising awareness of eye health. As the demand for innovative therapies and improved care options grows, this sector is expected to expand significantly by the end of the decade. Below is a detailed look at the market size, key players, driving factors, emerging trends, and segmentation shaping the night blindness treatment landscape.

Projected Market Expansion and Size of the Night Blindness Treatment Industry
The night blindness treatment market is forecasted to reach a value of $5.66 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.1%. This anticipated growth is supported by increasing investments in eye health initiatives, a surge in demand for tailored therapies, broader applications of gene therapy, enhancement of healthcare infrastructures, and more favorable reimbursement policies. Key trends influencing this growth include the rising prevalence of vitamin A deficiency, wider adoption of early diagnostic techniques, advances in minimally invasive eye surgery procedures, expanded use of nutritional and preventive treatments, and better access to vision care in emerging markets.

Download a free report of the night blindness treatment market report:
https://www.thebusinessresearchcompany.com/report/night-blindness-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Prominent Companies Leading the Night Blindness Treatment Market
Several influential corporations are at the forefront of the night blindness treatment industry. Notable names include Johnson & Johnson Private Limited, Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc, Bausch Health Companies Inc, Cipla Inc, Nature's Way, Garden of Life, Apellis Pharmaceuticals Inc, Solgar, Acucela Inc, Swanson Health Products, Astellas Pharma Inc, F. Hoffmann?La Roche Ltd, Applied Genetic Technologies Corp, MeiraGTx Holdings plc, GenSight Biologics, Santen Pharmaceutical Co Ltd, Alimera Sciences Inc, Opthea Limited, Oxurion NV, EyePoint Pharmaceuticals Inc, and Ocuphire Pharma Inc.

Significant Strategic Alliance in Gene Therapy Development
In October 2025, AviadoBio Ltd., a UK-based company specializing in targeted gene therapies for neurodegenerative and ocular diseases, signed an exclusive option-license deal with UgeneX Therapeutics. This agreement aims to develop and possibly commercialize UGX-202, an optogenetics-based gene therapy designed to restore vision for patients with retinitis pigmentosa and other inherited retinal disorders. AviadoBio intends to strengthen its portfolio of next-generation ocular gene therapies by utilizing UgeneX's advanced AAV-based optogenetic platform, which targets severe photoreceptor loss and related night blindness. UgeneX Therapeutics, headquartered in China, focuses on ophthalmic gene therapy innovations, supported by a proprietary technology platform and a growing pipeline of retinal treatment candidates.

View the full night blindness treatment market report:
https://www.thebusinessresearchcompany.com/report/night-blindness-treatment-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends Highlighting Innovation and Collaboration
Leading players in the temporary mechanical circulatory support (tMCS) device sector are increasingly forming partnerships to drive innovation. For example, in November 2025, VenstraMedical, an Australian cardiovascular medical device firm, partnered with Highcroft Capital, a venture capital firm based in the US. This collaboration secured strategic funding to accelerate the development of VenstraMedical's next-generation percutaneous ventricular assist device (pVAD). The device is a catheter-based pump designed for full ventricular unloading and hemodynamic support in patients facing cardiogenic shock or undergoing complex coronary procedures. Protected by multiple patents, it allows minimally invasive insertion and can deliver up to 7 liters per minute of cardiac output. This partnership reflects VenstraMedical's goal to revolutionize the tMCS market, valued at over $2 billion, with plans to advance toward clinical trials and commercialization.

Comprehensive Segmentation of the Night Blindness Treatment Market
This report segments the night blindness treatment market in multiple ways:

By Treatment Type:
- Medication
- Surgery
- Other Treatments

By Diagnostic Method:
- Blood Tests
- Color Vision Testing
- Pupil Light Reflex
- Refraction
- Retinal Exam
- Electroretinogram (ERG)
- Other Diagnostic Procedures

By Symptom:
- Eye Pain
- Cloudy Vision
- Halos
- Light Sensitivity
- Distance Vision Problems
- Other Symptoms

By End User:
- Clinics
- Hospitals
- Other Healthcare Facilities

Detailed Subsegments Include:
- Medication: Vitamin A Supplements, Retinoid Therapy, Beta-Carotene Supplements, Anti-Glaucoma Medications
- Surgery: Cataract Surgery, Retinal Surgery, Corneal Transplantation, LASIK Surgery
- Other Treatments: Light Therapy, Gene Therapy, Low Vision Aids and Assistive Devices, Nutritional Therapy

This thorough segmentation provides a clear framework for understanding the diverse treatment options, diagnostic approaches, and patient needs within the night blindness treatment market.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.